Biohit Oyj - Managers’ Transactions, August 22, 2017 at 1:55 pm local time (EEST)
Biohit Oyj has received the following notification.
| Person subject to the notification requirement | ||
| Name: | Korpela, Semi | |
| Position: | Chief Executive Officer | |
| Initial Notification | ||
| Reference number: | 74370089ATTSNBXJVT29_20170822112601_8 | |
| Issuer | ||
| Name: | Biohit Oyj | |
| LEI: | 74370089ATTSNBXJVT29 | |
| Transaction details | ||
| Transaction date: | 2017-08-17 | |
| Venue: | NASDAQ HELSINKI LTD (XHEL) | |
| Nature of the transaction: | Exercise (Rights, Put and Call Options) | |
| Further details: | ||
| Linked to stock option programme | ||
| Instrument: | Financial Instrument Linked to a Share or a Debt Instrument | |
| ISIN: | FI4000219324 | |
| Volume: | 32274 | |
| Unit price: | 3,16770 Euro | |
| Aggregated transactions | ||
| Volume: | 32274 | |
| Volume weighted average price: | 3.16770 Euro | |
| Transaction details | ||
| Transaction date: | 2017-08-17 | |
| Venue: | NASDAQ HELSINKI LTD (XHEL) | |
| Nature of the transaction: | Subscription | |
| Further details: | ||
| Linked to stock option programme | ||
| Instrument: | Financial Instrument Linked to a Share or a Debt Instrument | |
| ISIN: | FI4000219324 | |
| Volume: | 7726 | |
| Unit price: | 2,27660 Euro | |
| Aggregated transactions | ||
| Volume: | 7726 | |
| Volume weighted average price: | 2.27660 Euro | |
| Transaction details | ||
| Transaction date: | 2017-08-17 | |
| Venue: | NASDAQ HELSINKI LTD (XHEL) | |
| Nature of the transaction: | Disposal | |
| Further details: | ||
| Linked to stock option programme | ||
| Instrument: | Financial Instrument Linked to a Share or a Debt Instrument | |
| ISIN: | FI4000219324 | |
| Volume: | 7726 | |
| Unit price: | 0,00000 Euro | |
| Aggregated transactions | ||
| Volume: | 7726 | |
| Volume weighted average price: | 0.00000 Euro | |
Additional information:
CEO Semi Korpela, Biohit Oyj
tel. +358 9 773 861
investor.relations@biohit.fi
www.biohithealthcare.com
Biohit in brief
Biohit Oyj is a globally operating Finnish biotechnology company. Biohit’s mission is “Innovating for Health” – we produce innovative products and services to promote research and early diagnosis. Biohit is headquartered in Helsinki, Finland, and has subsidiaries in Italy and the UK. Biohit’s Series B share (BIOBV) is quoted on Nasdaq Helsinki in the Small cap/Healthcare group. www.biohithealthcare.com
